Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

CING vs ANRO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ANRO Wins Head-to-Head Institutional Verdict (2–2 across 6 Pillars · 4–1 Matrix Metrics)

ANRO Overall Winner 6-Pillar Tally: CING 2 – 2 ANRO (2 Tie) Matrix Metrics: CING 1 – 4 ANRO

As of Nov 17, 2026, Alto Neuroscience Inc. (ANRO) is the stronger overall head-to-head candidate over Cingulate Inc. (CING) in the Tradestie Institutional Equity Comparison Engine, winning 4–1 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). CING carries a Unified Composite Score of 44.8/100 (HOLD) at $4.76 (N/M Forward P/E, 0.0% operating margin), whereas ANRO carries 34.3/100 (SELL) at $25.11 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While CING currently prints a higher short-term Unified Composite Score (44.8/100 HOLD vs. ANRO 34.3/100 SELL), ANRO captures the overall institutional head-to-head verdict (4–1 matrix metrics and 2–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY).
  • Technical & Structure Timing Caution: CING is currently in a Breakdown options structure phase (RSI 51.8); meanwhile ANRO is in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 49.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CING vs ANRO
CING NASDAQ
Cingulate Inc. Common Stock
Pharmaceutical Preparations
$4.76
+26.93% 1D
Market Cap $62.5M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.13β · 117% Vol
Unified Composite Score
44.8 / 100 HOLD
Tech 31.0 Fund 50.0 Flow 67.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 52
RSI-14: 51.8 · SMA20: $4.71 · SMA50: $4.82
ANRO NYSE Head-to-Head Winner
Alto Neuroscience Inc.
Pharmaceutical Preparations
$25.11
-7.41% 1D
Market Cap $1.2B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 2.02β · 93% Vol
Unified Composite Score
34.3 / 100 SELL
Tech 15.0 Fund 38.0 Flow 64.0 Mom 40.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -12.8%) with fading momentum, RSI 50
RSI-14: 49.7 · SMA20: $24.90 · SMA50: $25.99

6-Pillar Scorecard Institutional Category Breakdown (CING 2 – 2 ANRO)

Columns: Metric · CING · ANRO
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale ANRO
Revenue Growth (YoY) +0.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A N/A
Market Cap $62.5M $1.2B
3. Profitability & Quality ANRO
Gross Margin N/A N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -198.7% -46.7%
4. Balance Sheet & Cash Flow CING
Cash Generation (TTM) -$21M -$80M
Cash Flow Margin N/A N/A
Net Cash / Leverage $22M Net Cash $301M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CING
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 111.1% (16th %ile) 79.4% (8th %ile)
Put/Call OI Skew 0.07x (Call-Skewed) 0.04x (Call-Skewed)
OBV Trend / Tech Phase ACCUMULATION · Neutral ACCUMULATION · Distribution
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CING (1) vs ANRO (4)
Institutional Metric CING ANRO Criterion Row Edge
Market Capitalization
Scale
$62.5M $1.2B Larger Scale ANRO
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +0.0% Higher Growth Tie
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-198.7% -46.7% Higher ROE ANRO
52-Week Range Position
Momentum
18% ($3–$12) 54% ($11–$37) Stronger Trend ANRO
Beta / 30D Volatility
Risk Regime
1.13β · 117% Vol 2.02β · 93% Vol Lower Realized Risk ANRO
Unified Institutional Score
Composite Signal
44.8 / 100 (HOLD) 34.3 / 100 (SELL) Higher Composite CING
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$21M ($22M Net Cash) -$80M ($301M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ANRO +0.87 pp
CING: +9.17% · ANRO: +10.04%
3M Horizon CING +18.35 pp
CING: -9.68% · ANRO: -28.03%
6M Horizon ANRO +14.36 pp
CING: +8.43% · ANRO: +22.79%
1Y Horizon ANRO +70.96 pp
CING: +36.39% · ANRO: +107.35%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CING vs ANRO. Trailing 12-month operating profitability (CING 0.0% vs ANRO 0.0%) and valuation multiples (CING N/M vs ANRO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

CING ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-198.7% · N/M
ANRO ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-46.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CING BREAKDOWN
170d in phase · OBV ACCUMULATION
Current IV 111.1%
IV Percentile 16th %ile
Put/Call OI Skew 0.07x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact CING Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ANRO BREAKDOWN
58d in phase · OBV ACCUMULATION
Current IV 79.4%
IV Percentile 8th %ile
Put/Call OI Skew 0.04x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact ANRO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CING Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $62.5M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ANRO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.2B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CING vs ANRO Key Questions & Quantitative Answers

As of Nov 17, 2026, Alto Neuroscience Inc. (ANRO) is the stronger overall head-to-head candidate over Cingulate Inc. (CING) in the Tradestie Institutional Equity Comparison Engine, winning 4–1 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). CING carries a Unified Composite Score of 44.8/100 (HOLD) at $4.76 (N/M Forward P/E, 0.0% operating margin), whereas ANRO carries 34.3/100 (SELL) at $25.11 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While CING currently prints a higher short-term Unified Composite Score (44.8/100 HOLD vs. ANRO 34.3/100 SELL), ANRO captures the overall institutional head-to-head verdict (4–1 matrix metrics and 2–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY). Technical & Structure Timing Caution: CING is currently in a Breakdown options structure phase (RSI 51.8); meanwhile ANRO is in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 49.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ANRO leads the Growth & Scale pillar: CING posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with ANRO at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, CING generates N/A in USD-normalized revenue versus N/A for ANRO. In operating R&D and SG&A reinvestment, CING deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ANRO.

CING and ANRO trade at balanced relative valuation multiples. CING trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas ANRO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CING (-198.7% ROE) versus ANRO (-46.7% ROE) capital efficiency.

In options market volatility and institutional positioning, CING carries 111.1% implied volatility (16th %ile, Compressed (<25th %ile)), a 0.07x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.13β · 117% Vol realized risk). By comparison, ANRO carries 79.4% implied volatility (8th %ile, Compressed (<25th %ile)), a 0.04x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (2.02β · 93% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.